The Auxiliary Effects of Low-Molecular-Weight Fucoidan in Locally Advanced Rectal Cancer Patients Receiving Neoadjuvant Concurrent Chemoradiotherapy Before Surgery: A Double-Blind, Randomized, Placebo-Controlled Study
Patients with cancer use low-molecular-weight fucoidan (LMF) as a supplement to therapy. However, most studies of LMF are in vitro or conducted using animals. Concurrent chemoradiotherapy (CCRT) is the gold standard for locally advanced rectal cancer (LARC). This study investigated the quality of li...
Main Authors: | Hsiang-Lin Tsai MD, PhD, Yung-Sung Yeh MD, Po-Jung Chen MD, Yu-Tang Chang MD, Yen-Cheng Chen MD, Wei-Chih Su MD, Tsung-Kun Chang MD, Ching-Wen Huang MD, PhD, Jaw-Yuan Wang MD, PhD |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2023-10-01
|
Series: | Integrative Cancer Therapies |
Online Access: | https://doi.org/10.1177/15347354231187153 |
Similar Items
-
Severe Radiation-Induced Lymphopenia Attenuates the Benefit of Durvalumab After Concurrent Chemoradiotherapy for NSCLC
by: Wang Jing, MD, et al.
Published: (2022-09-01) -
F-FDG PET/CT Parameters for Predicting Prognosis in Esophageal Cancer Patients Treated With Concurrent Chemoradiotherapy
by: Seokmo Lee MD, PhD, et al.
Published: (2021-07-01) -
Sweet syndrome in a patient with rectal adenocarcinoma and HIV following neoadjuvant chemoradiation
by: Kamina Wilkerson, BS, et al.
Published: (2024-01-01) -
Symptomatic Pneumonitis With Durvalumab After Concurrent Chemoradiotherapy in Unresectable Stage III NSCLC
by: Johan F. Vansteenkiste, MD, PhD, et al.
Published: (2024-03-01) -
Impact of Lymphopenia Recovery After Chemoradiotherapy on Durvalumab Consolidation Therapy in Stage III NSCLC
by: Tomoki Kuge, MD, et al.
Published: (2023-05-01)